SAN and SNY Related Headlines
Go Back- Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
- Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
- Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
- Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
- Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
- Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
- Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
- Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
- Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
- Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
- Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
- Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
- Sanofi (SNY) issues Statement on FTC challenge to proposed license agreement with Maze Therapeutics
- Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
- Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alon
- Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
- Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
- Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
- Sanofi (SNY) tumbles on 2024 profit warning
- Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
- Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
- GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide
- Sanofi Bridging the Gap between the Homeless and Society via Futsal
- Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
- Sanofi (SNY) Said To Explore Acquisition Of Cancer Drugmaker Mirati (MRTX) - Bloomberg
- Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
- Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
- Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
- Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
- Press release: Online availability of Sanofi’s half-year financial report for 2023
- Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
- Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
- Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
- Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
- Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
- Sanofi (SNY) and Maze Therapeutics Enter Worldwide License Agreement for MZE001
- Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease
- Press Release: Sanofi completes acquisition of Provention Bio, Inc.
- Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
- Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
SAN and SNY Related Press Releases
Go Back- Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
- Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
- Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
- Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
- Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
- Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
- Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
- Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
- Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
- Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
- Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
- Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
- Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
- Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alon
- Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
- Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
- Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
- Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
- Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
- GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide
- Sanofi Bridging the Gap between the Homeless and Society via Futsal
- Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
- Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
- Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
- Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
- Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
- Press release: Online availability of Sanofi’s half-year financial report for 2023
- Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
- Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
- Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
- Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
- Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
- Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease
- Press Release: Sanofi completes acquisition of Provention Bio, Inc.
- Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
- Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
SAN and SNY Related SEC Filings
Go Back- Form 6-K Sanofi For: Mar 31
- Form F-3ASR Sanofi
- Form S-8 Sanofi
- Form 6-K Sanofi For: Mar 20
- Form S-8 POS Sanofi
- Form 6-K Sanofi For: Feb 27
- Form IRANNOTICE Sanofi
- Form 20-F Sanofi For: Dec 31
- Form 6-K Sanofi For: Feb 15
- Form SC 13G/A Sanofi Filed by: Amundi
- Form SC 13G/A Sanofi Filed by: DODGE & COX
- Form SC 13G/A Sanofi Filed by: BlackRock Inc.
- Form 6-K Sanofi For: Feb 02
- Form 6-K Sanofi For: Dec 31
- Form 6-K Sanofi For: Jan 23
- Form 6-K Sanofi For: Jan 17
- Form 6-K Sanofi For: Dec 27
- Form 6-K Sanofi For: Dec 20
- Form F-6EF Sanofi Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary
- Form 6-K Sanofi For: Dec 01
- Form 6-K Sanofi For: Sep 30
- Form 6-K Sanofi For: Oct 27
- Form 6-K Sanofi For: Oct 26
- Form 6-K Sanofi For: Oct 20
- Form 6-K Sanofi For: Oct 11
- Form 6-K Sanofi For: Sep 27
- Form 6-K Sanofi For: Sep 05
- Form 6-K Sanofi For: Aug 10
- Form 6-K Sanofi For: Jun 30
- Form 6-K Sanofi For: Jul 28
- Form 6-K Sanofi For: Jun 30
- Form 6-K Sanofi For: Jul 24
- Form 6-K Sanofi For: Jul 05
- Form 11-K Sanofi For: Dec 31
- Form 11-K Sanofi For: Dec 31
- Form 6-K Sanofi For: Jun 20
- Form 6-K Sanofi For: Jun 02
- Form SD Sanofi
- Form 6-K Sanofi For: May 23
- Form 6-K Sanofi For: Mar 31
- Form 6-K Sanofi For: Apr 27
